Executive Chairman of the Board and Interim CEO
Carl Hull co-founded Maravai in 2014 and served as its Chief Executive Officer for eight years, during which time he oversaw an extraordinary period of growth and operational expansion and the company’s initial public offering. He has over 35 years of sales, marketing and general management leadership in the diagnostics and life sciences industries. Prior to founding Maravai LifeSciences, Mr. Hull was CEO of Gen-Probe, where he had been recruited in 2007 as part of a board-directed succession plan for the CEO. He focused the company strategy to take full advantage of its core molecular diagnostics and automation strengths. During his tenure, the value of Gen-Probe doubled, creating nearly $2 billion in value for shareholders and culminating in a successful sale of the business in 2012 to Hologic. Earlier in his career, Mr. Hull had been in sales, marketing and management positions for Abbott Laboratories, Ventana Medical Systems (acquired by Roche), Applied Imaging (now part of Danaher) and Applied Biosystems (now part of Thermo Fisher Scientific). Mr. Hull holds an MBA from the University of Chicago and a B.A. in political science and international relations from the Johns Hopkins University.
Executive Vice President and Chief Financial Officer
Kevin Herde is an experienced financial management executive with over 25 years of experience in finance, accounting and general management focusing on diagnostics, biopharmaceutical development and technology. Mr. Herde joined Maravai LifeSciences from Sorrento Therapeutics, where he was most recently Executive Vice President and Chief Financial Officer. Prior to Sorrento Therapeutics, Mr. Herde served as Vice President of Global Blood Screening at Hologic. There he worked in conjunction with the company’s strategic partners at Grifols and Novartis, managing a multinational business providing molecular diagnostics solutions to improve blood safety. Mr. Herde also worked with Carl Hull and Eric Tardif as Vice President, Finance and Corporate Controller for Gen-Probe prior to its acquisition by Hologic in 2012. Mr. Herde is a CPA and began his career with KPMG. Mr. Herde holds a B.B.A. in business administration from University of San Diego.
Executive Vice President and Chief Administrative Officer
Pete Leddy has over 30 years of experience leading growth and change across a wide variety of businesses, and specifically in scaling global healthcare companies. Throughout 2022, Pete worked as a consultant to Maravai on a number of issues related to organizational design, compensation and retention before joining the Company as CAO. Previously, Pete served as Chief Human Resources Officer at Berkeley Lights, Chief People Officer at dosist, Executive Vice President, Global Human Resources and Corporate Integrity at Nuvasive and Chief Human Resources Officer at Life Technologies and Invitrogen. Earlier in his career he held a variety of executive and human resource positions at Dell, Promus Hotel Corp. and PepsiCo. He received his B.A. in Psychology from Creighton University and his M.S. and Ph.D. degrees in industrial/organizational psychology from the Illinois Institute of Technology.
Chief Operating Officer, Nucleic Acid Production
Brian Neel has served as the Chief Operating Officer for Maravai LifeSciences’ Nucleic Acid Production business segment since October 2017. Prior to his current role, Mr. Neel was Vice President of Operations of Codex DNA. Prior to joining Codex, he was Vice President of Operations of GenMark Diagnostics and previously served as the Site Manufacturing Operations Leader at Thermo Fisher Scientific. Mr. Neel holds a B.S. in microbiology from the University of Missouri.
President, Biologics Safety Testing
Trey Martin has more than 25 years of executive leadership experience in life sciences operations, engineering, sales, and marketing. Prior to joining Maravai, he was most recently Senior Vice President, Genomic Medicines, part of Danaher Corporation, where he oversaw new business creation in the areas of mRNA, gene editing and gene therapy. Mr. Martin originally joined Danaher with the acquisition of Integrated DNA Technologies (IDT) in 2018, serving as President of IDT. Prior to the acquisition by Danaher, Mr. Martin held positions of increasing responsibility over his more than two decades of tenure at IDT and contributed to the consistent growth and competitiveness of the company’s primary oligo synthesis business through directing organic and inorganic growth investments, including product portfolio and service capability expansions, strategic customer collaborations and global M&A in the nucleic acid space. Mr. Martin holds a bachelor’s degree in biochemistry from the University of Iowa.
Chief Operating Officer, Biologics Safety Testing
Christine Dolan has served as the Chief Operating Officer of Maravai LifeSciences’ Biologics Safety Testing business segment since October 2017. Prior to joining Maravai, Ms. Dolan held several operational and business leadership roles including Senior Vice President of Product Development, VP of Global Operations and VPGM of Development and Analytical Services at Catalent Pharma Solutions. Prior to joining Catalent Pharma Solutions, she was Director of Nuclear Operations and Global Quality Control at GE Healthcare and Amersham Health. Dolan holds a B.S. in biology from Lenoir-Rhyne College.
Vice President, Strategy and Business Development
Deb Barbara joined Maravai in April 2022. Ms Barbara has over 30 years of experience in a variety of business development roles, most recently as Senior Director/General Manager, Nucleic Acid Therapeutics for Thermo Fisher Scientific. Prior to that, she was Vice President, Business Development at Strategic Diagnostics (SDIX). Prior to SDIX, Ms. Barbara was Vice President, Business Development and Licensing at Gene Logic/Ore Pharmaceuticals. Prior to Ore Pharmaceuticals, she spent seven years at Johns Hopkins University with her last role as Senior Director, Business/Technology Development, and 11 years at Amersham Life Science in progressive account management roles. Ms. Barbara holds an MBA from Loyola University Maryland and a B.S. in Biochemistry and Molecular Biology from the University of Maryland Baltimore County.
Vice President, Quality
Ericka Crawford joined Maravai LifeSciences as Vice President, Quality in August 2017 and has 25 years of experience in quality management, operations and strategic business planning. Prior to joining Maravai, Ms. Crawford was Director of Quality Assurance at Abbott Diagnostics where she oversaw the quality function for the Ibis division. Prior to Abbott Diagnostics, she was Senior Manager of Quality & Regulatory at Life Technologies. She also held several management roles at Oxis International, Bayer Pharmaceuticals, Serologicals and CryoLife. Ms. Crawford holds a B.S. in biology from Western Carolina University, MBA from Kennesaw State University, and doctorate in organizational leadership from Brandman University.
Executive Vice President, Secretary and General Counsel
Kurt Oreshack joined Maravai LifeSciences as General Counsel in November 2020. Prior to joining Maravai, Mr. Oreshack was a partner at Breakwater Law Group, practicing in the field of corporate and securities law. Prior to joining Breakwater Law Group, he was the General Counsel of Human Longevity, and previously practiced law individually and as General Counsel in Residence at Gunderson Dettmer Stough Villeneuve Franklin & Hachigian. Mr. Oreshack received a J.D. from the University of Notre Dame Law School and a B.A. from Loyola University Chicago. He is a member of the State Bar of California.
Vice President, Marketing
Doreen Pippen joined Maravai LifeSciences as Vice President, Marketing in January 2021 and has extensive experience in market development, product management, strategy and marketing leadership for scientific consumables and instrument services. She was most recently Senior Vice President of Business Development and Product Leader at Science and Medicine Group. She also held several management roles at Thermo Fisher Scientific in customer loyalty, global service and support, as well as market development and product management for the Protein Analysis, Epigenetics and qPCR portfolios. Ms. Pippen holds an MBA from National University and a B.A. in biology from the University of San Diego.